Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bluebird Bio
Pharma
bluebird investors get on board with sale to Carlyle, SK Capital
Carlyle and SK Capital expect to complete the acquisition of bluebird bio on Monday.
Kevin Dunleavy
May 30, 2025 11:50am
Bluebird investor reluctance pays off with better buyout offer
May 14, 2025 10:40am
Bluebird warns of potential bankruptcy amid buyout delay
May 13, 2025 9:56am
Bluebird bio sticks with Carlyle and SK Capital deal
Apr 16, 2025 9:30am
Bluebird bio receives rival M&A bid worth 50% higher
Mar 28, 2025 7:14pm
Once valued at $10B, struggling bluebird bio sold for $29M
Feb 21, 2025 10:56am
